Longitudinal MRI-PDFF Quantification of Hepatic Steatosis Reversibility During SGLT2-Inhibitor versus GLP-1 Receptor Agonist Therapy: A Prospective Cohort Study
Sriwijaya Journal of Radiology and Imaging Research · 15.07.2026 · 3 (2) · 101-108
DOI: 10.59345/sjrir.v3i2.292 ↗Kurz gefasst
Kohortenstudie in der Zeitschrift Sriwijaya Journal of Radiology and Imaging Research, online erschienen am 15.07.2026. Verfasst von Arsan Saliha und 3 weiteren Autor:innen.
Abstract (Originalsprache)
Background
Precise quantification of hepatic steatosis is central to managing metabolic dysfunction-associated steatotic liver disease (MASLD). MRI proton density fat fraction (MRI-PDFF) has displaced biopsy as a reproducible biomarker, yet real-world comparative monitoring data and formal early-response prediction remain scarce in Indonesian practice. We quantified steatosis reversibility on serial MRI-PDFF during SGLT2-inhibitor versus GLP-1 receptor agonist therapy and tested whether an early scan predicts response.
Methods
In this prospective cohort at a tertiary hospital in Palembang, Indonesia, 90 adults with MASLD (baseline PDFF ≥5.5%) were grouped by prescribed therapy (SGLT2i, n=45; GLP-1 RA, n=45) and imaged at baseline, Month 3 and Month 6 on a 3.0 T scanner using a confounder-corrected 3D multi-echo spoiled gradient-echo sequence. Two blinded radiologists measured PDFF across Couinaud segments V/VI/VIII; response was a ≥30% relative reduction. Analyses (STARD 2015) included linear mixed-effects modelling, κ and intraclass correlation, ROC (DeLong), likelihood ratios and multivariable logistic regression.
Results
PDFF fell in both arms (both p
Zitieren
APA
Saliha, A., Sucipto, D., Adella, M. C., & Perez, E. D. (2026). Longitudinal MRI-PDFF Quantification of Hepatic Steatosis Reversibility During SGLT2-Inhibitor versus GLP-1 Receptor Agonist Therapy: A Prospective Cohort Study. Sriwijaya Journal of Radiology and Imaging Research, 3(2), 101-108. https://doi.org/10.59345/sjrir.v3i2.292
Vancouver
Saliha A, Sucipto D, Adella MC, Perez ED. Longitudinal MRI-PDFF Quantification of Hepatic Steatosis Reversibility During SGLT2-Inhibitor versus GLP-1 Receptor Agonist Therapy: A Prospective Cohort Study. Sriwijaya Journal of Radiology and Imaging Research. 2026;3(2):101-108. doi:10.59345/sjrir.v3i2.292
BibTeX
@article{Saliha2026,
author = {Saliha, Arsan and Sucipto, Dedi and Adella, Mischa Chantal and Perez, Ericca Dominique},
title = {Longitudinal MRI-PDFF Quantification of Hepatic Steatosis Reversibility During SGLT2-Inhibitor versus GLP-1 Receptor Agonist Therapy: A Prospective Cohort Study},
journal = {Sriwijaya Journal of Radiology and Imaging Research},
year = {2026},
volume = {3},
number = {2},
pages = {101--108},
doi = {10.59345/sjrir.v3i2.292}
}
EUVIMED